Vascular actions of adipokines. Molecular mechanisms and therapeutic implications

Advances in Pharmacology

Volumn 60, Issue C, 2010, Pages 229-255

  Xu, Aimin ^a   Wang, Yu ^a   Lam, Karen S L ^a   Vanhoutte, Paul M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adipokines; Adiponectin; Adipose tissue; Endothelial dysfunction; Inflammation; Obesity

Indexed keywords

ADIPOCYTOKINE; FATTY ACID BINDING PROTEIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

ADIPOSE TISSUE; APOPTOSIS; ATHEROSCLEROSIS; BOOK; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL DYSFUNCTION; HOMEOSTASIS; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; VASCULAR DISEASE; VASCULITIS; ANIMAL; BLOOD VESSEL; DRUG EFFECT; HUMAN; METABOLISM; REVIEW;

ADIPOKINES; ANIMALS; BLOOD VESSELS; HUMANS;

EID: 78349237728     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385061-4.00008-8     Document Type: Chapter

References (128)

1. Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Natural Medicines 2001, 7:947-953.
2. Boord J.B., Maeda K., Makowski L., Babaev V.R., Fazio S., Linton M.F., Hotamisligil G.S. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2002, 22:1686-1691.
3. Boord J.B., Maeda K., Makowski L., Babaev V.R., Fazio S., Linton M.F., Hotamisligil G.S. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004, 110:1492-1498. Epub 2004 Sep 1497.
4. Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nature Reviews 2010, 9:107-115.
5. Chatterjee T.K., Stoll L.L., Denning G.M., Harrelson A., Blomkalns A.L., Idelman G., Rothenberg F.G., Neltner B., Romig-Martin S.A., Dickson E.W., et al. Proinflammatory phenotype of perivascular adipocytes: Influence of high-fat feeding. Circulation Research 2009, 104:541-549.
6. Chen H., Montagnani M., Funahashi T., Shimomura I., Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. The Journal of Biological Chemistry 2003, 278:45021-45026.
7. Cheng K.K., Iglesias M.A., Lam K.S., Wang Y., Sweeney G., Zhu W., Vanhoutte P.M., Kraegen E.W., Xu A. APPL1 potentiates insulin-mediated inhibition of hepatic glucose production and alleviates diabetes via Akt activation in mice. Cell Metabolism 2009, 9:417-427.
8. Cheng K.K., Lam K.S., Wang Y., Huang Y., Carling D., Wu D., Wong C., Xu A. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 2007, 56:1387-1394.
9. Chow W.S., Cheung B.M., Tso A.W., Xu A., Wat N.M., Fong C.H., Ong L.H., Tam S., Tan K.C., Janus E.D., et al. Hypoadiponectinemia as a predictor for the development of hypertension: A 5-year prospective study. Hypertension 2007, 49:1455-1461.
10. Clasen R., Schupp M., Foryst-Ludwig A., Sprang C., Clemenz M., Krikov M., Thone-Reineke C., Unger T., Kintscher U. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005, 46:137-143. Epub 2005 Jun 2006.
11. Coe N.R., Simpson M.A., Bernlohr D.A. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. Journal of Lipid Research 1999, 40:967-972.
12. Combs T.P., Berg A.H., Obici S., Scherer P.E., Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. The Journal of Clinical Investigation 2001, 108:1875-1881.
13. Ding X., Saxena N.K., Lin S., Xu A., Srinivasan S., Anania F.A. The roles of leptin and adiponectin: A novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. The American Journal of Pathology 2005, 166:1655-1669.
14. Erbay E., Babaev V.R., Mayers J.R., Makowski L., Charles K.N., Snitow M.E., Fazio S., Wiest M.M., Watkins S.M., Linton M.F., et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nature Medicine 2009, 15:1383-1391.
15. Fadini G.P., Sartore S., Agostini C., Avogaro A. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care 2007, 30:1305-1313.
16. Félétou M., Vanhoutte P.M. Endothelial dysfunction: A multifaceted disorder (The Wiggers Award Lecture). American Journal of Physiology. Heart and Circulatory Physiology 2006, 291:H985-H1002.
17. Fesus G., Dubrovska G., Gorzelniak K., Kluge R., Huang Y., Luft F.C., Gollasch M. Adiponectin is a novel humoral vasodilator. Cardiovascular Research 2007, 75:719-727.
18. Frizzell N., Rajesh M., Jepson M.J., Nagai R., Carson J.A., Thorpe S.R., Baynes J.W. Succination of thiol groups in adipose tissue proteins in diabetes: Succination inhibits polymerization and secretion of adiponectin. The Journal of Biological Chemistry 2009, 284:25772-25781.
19. Fruebis J., Tsao T.S., Javorschi S., Ebbets-Reed D., Erickson M.R., Yen F.T., Bihain B.E., Lodish H.F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:2005-2010.
20. Fu Y., Luo N., Lopes-Virella M.F. Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. Journal of Lipid Research 2000, 41:2017-2023.
21. Fu Y., Luo N., Lopes-Virella M.F., Garvey W.T. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 2002, 165:259-269.
22. Furuhashi M., Hotamisligil G.S. Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nature Reviews 2008, 7:489-503.
23. Furuhashi M., Tuncman G., Gorgun C.Z., Makowski L., Atsumi G., Vaillancourt E., Kono K., Babaev V.R., Fazio S., Linton M.F., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007, 447:959-965.
24. Furuhashi M., Ura N., Higashiura K., Murakami H., Tanaka M., Moniwa N., Yoshida D., Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003, 42:76-81.
25. Galvez B., de Castro J., Herold D., Dubrovska G., Arribas S., Gonzalez M.C., Aranguez I., Luft F.C., Ramos M.P., Gollasch M., et al. Perivascular adipose tissue and mesenteric vascular function in spontaneously hypertensive rats. Arteriosclerosis, Thrombosis, and Vascular biology 2006, 26:1297-1302.
26. Gao Y.J. Dual modulation of vascular function by perivascular adipose tissue and its potential correlation with adiposity/lipoatrophy-related vascular dysfunction. Current Pharmaceutical Design 2007, 13:2185-2192.
27. Goldstein B.J., Scalia R. Adipokines and vascular disease in diabetes. Current Diabetes Reports 2007, 7:25-33.
28. Greenstein A.S., Khavandi K., Withers S.B., Sonoyama K., Clancy O., Jeziorska M., Laing I., Yates A.P., Pemberton P.W., Malik R.A., et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009, 119:1661-1670.
29. Gustafsson S., Lind L., Soderberg S., Ingelsson E. Associations of circulating adiponectin with measures of vascular function and morphology. The Journal of Clinical Endocrinology and Metabolism 2010, 95:2927-2934.
30. Haider D.G., Schindler K., Bohdjalian A., Prager G., Luger A., Wolzt M., Ludvik B. Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity. Diabetes, Obesity and Metabolism 2007, 9:761-763.
31. Hattori Y., Suzuki M., Hattori S., Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003, 46:1543-1549.
32. Higuchi A., Ohashi K., Kihara S., Walsh K., Ouchi N. Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factor-alpha expression. Circulation Research 2009, 104:1058-1065.
33. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
34. Hoo R.C., Yeung C.Y., Lam K.S., Xu A. Inflammatory biomarkers associated with obesity and insulin resistance: A focus on lipocalin-2 and adipocyte fatty acid-binding protein. Expert Review of Endocrinology and Metabolism 2008, 3:29-41.
35. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
36. Hsu B.G., Chen Y.C., Lee R.P., Lee C.C., Lee C.J., Wang J.H. Fasting serum level of fatty-acid-binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Circulation Journal 2010, 74:327-331.
37. Hui X., Li H., Zhou Z., Lam K.S., Xiao Y., Wu D., Ding K., Wang Y., Vanhoutte P.M., Xu A. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. The Journal of Biological Chemistry 2010, 285:10273-10280.
38. Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003, 52:1655-1663.
39. Kawamoto A., Losordo D.W. Endothelial progenitor cells for cardiovascular regeneration. Trends in Cardiovascular Medicine 2008, 18:33-37.
40. Kazemi M.R., McDonald C.M., Shigenaga J.K., Grunfeld C., Feingold K.R. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arteriosclerosis, Thrombosis, and Vascular Biology 2005, 25:1220-1224.
41. Kobashi C., Urakaze M., Kishida M., Kibayashi E., Kobayashi H., Kihara S., Funahashi T., Takata M., Temaru R., Sato A., et al. Adiponectin inhibits endothelial synthesis of Interleukin-8. Circulation Research 2005, 97:1245-1252.
42. Kobayashi H., Ouchi N., Kihara S., Walsh K., Kumada M., Abe Y., Funahashi T., Matsuzawa Y. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circulation Research 2004, 94:e27-31.
43. Koh K.K., Han S.H., Quon M.J., Yeal Ahn J., Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005, 28:1419-1424.
44. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., Kang M.H., Ahn T.H., Choi I.S., Shin E.K. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687-3692.
45. Kubota N., Terauchi Y., Yamauchi T., Kubota T., Moroi M., Matsui J., Eto K., Yamashita T., Kamon J., Satoh H., Yano W., Froguel P., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. Journal of Biological Chemistry 2002, 25863-25866.
46. Kubota N., Terauchi Y., Kubota T., Kumagai H., Itoh S., Satoh H., Yano W., Ogata H., Tokuyama K., Takamoto I., et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. The Journal of Biological Chemistry 2006, 281:8748-8755.
47. Lam K.S., Xu A. Adiponectin: Protection of the endothelium. Current Diabetes Reports 2005, 5:254-259.
48. Li C.J., Sun H.W., Zhu F.L., Chen L., Rong Y.Y., Zhang Y., Zhang M. Local adiponectin treatment reduces atherosclerotic plaque size in rabbits. The Journal of Endocrinology 2007, 193:137-145.
49. Lin L.Y., Lin C.Y., Su T.C., Liau C.S. Angiotensin II-induced apoptosis in human endothelial cells is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90. FEBS Letters 2004, 574:106-110.
50. Llaverias G., Noe V., Penuelas S., Vazquez-Carrera M., Sanchez R.M., Laguna J.C., Ciudad C.J., Alegret M. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochemical and Biophysical Research Communications 2004, 318:265-274.
51. Makowski L., Boord J.B., Maeda K., Babaev V.R., Uysal K.T., Morgan M.A., Parker R.A., Suttles J., Fazio S., Hotamisligil G.S., et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nature Medicine 2001, 7:699-705.
52. Makowski L., Brittingham K.C., Reynolds J.M., Suttles J., Hotamisligil G.S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. The Journal of Biological Chemistry 2005, 280:12888-12895.
53. Makowski L., Hotamisligil G.S. Fatty acid binding proteins-the evolutionary crossroads of inflammatory and metabolic responses. The Journal of Nutrition 2004, 134:2464S-2468S.
54. Mallamaci F., Zoccali C., Cuzzola F., Tripepi G., Cutrupi S., Parlongo S., Tanaka S., Ouchi N., Kihara S., Funahashi T., et al. Adiponectin in essential hypertension. Journal of Nephrology 2002, 15:507-511.
55. Matsuda M., Shimomura I., Sata M., Arita Y., Nishida M., Maeda N., Kumada M., Okamoto Y., Nagaretani H., Nishizawa H., et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. The Journal of Biological Chemistry 2002, 277:37487-37491.
56. Matsuo Y., Imanishi T., Kuroi A., Kitabata H., Kubo T., Hayashi Y., Tomobuchi Y., Akasaka T. Effects of plasma adiponectin levels on the number and function of endothelial progenitor cells in patients with coronary artery disease. Circulation Journal 2007, 71:1376-1382.
57. Mazurek T., Zhang L., Zalewski A., Mannion J.D., Diehl J.T., Arafat H., Sarov-Blat L., O'Brien S., Keiper E.A., Johnson A.G., et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003, 108:2460-2466.
58. Milner K.L., van der Poorten D., Xu A., Bugianesi E., Kench J.G., Lam K.S., Chisholm D.J., George J. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009, 49:1926-1934.
59. Miyoshi T., Onoue G., Hirohata A., Hirohata S., Usui S., Hina K., Kawamura H., Doi M., Kusano K.F., Kusachi S., et al. Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 2010, 211:164-169. [Epub ahead of print].
60. Mohlig M., Weickert M.O., Ghadamgadai E., Machlitt A., Pfuller B., Arafat A.M., Pfeiffer A.F., Schofl C. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. European Journal of Endocrinology 2007, 157:195-200.
61. Motoshima H., Wu X., Mahadev K., Goldstein B.J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochemical and Biophysical Research Communications 2004, 315:264-271.
62. Nakamura N., Naruse K., Matsuki T., Hamada Y., Nakashima E., Kamiya H., Matsubara T., Enomoto A., Takahashi M., Oiso Y., et al. Adiponectin promotes migration activities of endothelial progenitor cells via Cdc42/Rac1. FEBS Letters 2009, 583:2457-2463.
63. Nishimura M., Izumiya Y., Higuchi A., Shibata R., Qiu J., Kudo C., Shin H.K., Moskowitz M.A., Ouchi N. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 2008, 117:216-223.
64. Ohashi K., Kihara S., Ouchi N., Kumada M., Fujita K., Hiuge A., Hibuse T., Ryo M., Nishizawa H., Maeda N., et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006, 47:1108-1116.
65. Okamoto E., Couse T., De Leon H., Vinten-Johansen J., Goodman R.B., Scott N.A., Wilcox J.N. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 2001, 104:2228-2235.
66. Okamoto Y., Kihara S., Ouchi N., Nishida M., Arita Y., Kumada M., Ohashi K., Sakai N., Shimomura I., Kobayashi H., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
67. Osto E., Matter C.M., Kouroedov A., Malinski T., Bachschmid M., Camici G.G., Kilic U., Stallmach T., Boren J., Iliceto S., et al. c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. Circulation 2008, 118:2073-2080.
68. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
69. Ouchi N., Kobayashi H., Kihara S., Kumada M., Sato K., Inoue T., Funahashi T., Walsh K. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. The Journal of Biological Chemistry 2003, 13:13.
70. Ouchi N., Ohishi M., Kihara S., Funahashi T., Nakamura T., Nagaretani H., Kumada M., Ohashi K., Okamoto Y., Nishizawa H., et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42:231-234.
71. Ouedraogo R., Wu X., Xu S.Q., Fuchsel L., Motoshima H., Mahadev K., Hough K., Scalia R., Goldstein B.J. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: Evidence for involvement of a cAMP signaling pathway. Diabetes 2006, 55:1840-1846.
72. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., Tuncman G., Gorgun C., Glimcher L.H., Hotamisligil G.S. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306:457-461.
73. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., Gorgun C.Z., Hotamisligil G.S. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
74. Pajvani U.B., Du X., Combs T.P., Berg A.H., Rajala M.W., Schulthess T., Engel J., Brownlee M., Scherer P.E. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. The Journal of Biological Chemistry 2003, 278:9073-9085.
75. Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Doebber T., Berger J.P., Wagner J.A., Wu M., Knopps A., Xiang A.H., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. The Journal of Biological Chemistry 2004, 279:12152-12162.
76. Pelton P.D., Zhou L., Demarest K.T., Burris T.P. PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochemical and Biophysical Research Communications 1999, 261:456-458.
77. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
78. Rajsheker S., Manka D., Blomkalns A.L., Chatterjee T.K., Stoll L.L., Weintraub N.L. Crosstalk between perivascular adipose tissue and blood vessels. Current Opinion in Pharmacology 2010, 10:191-196.
79. Rhee E.J., Lee W.Y., Park C.Y., Oh K.W., Kim B.J., Sung K.C., Kim B.S. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. European Journal of Endocrinology 2009, 160:165-172.
80. Ricci R., Sumara G., Sumara I., Rozenberg I., Kurrer M., Akhmedov A., Hersberger M., Eriksson U., Eberli F.R., Becher B., et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 2004, 306:1558-1561.
81. Richards A.A., Colgrave M.L., Zhang J., Webster J., Simpson F., Preston E., Wilks D., Hoehn K.L., Stephenson M., Macdonald G.A., et al. Sialic acid modification of adiponectin is not required for multimerization or secretion but determines half-life in circulation. Molecular Endocrinology 2010, 24:229-239.
82. Ryo M., Nakamura T., Kihara S., Kumada M., Shibazaki S., Takahashi M., Nagai M., Matsuzawa Y., Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circulation Journal 2004, 68:975-981.
83. Sabio G., Das M., Mora A., Zhang Z., Jun J.Y., Ko H.J., Barrett T., Kim J.K., Davis R.J. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
84. Sambuceti G., Morbelli S., Vanella L., Kusmic C., Marini C., Massollo M., Augeri C., Corselli M., Ghersi C., Chiavarina B., et al. Diabetes impairs the vascular recruitment of normal stem cells by oxidant damage, reversed by increases in pAMPK, heme oxygenase-1, and adiponectin. Stem Cells 2009, 27:399-407.
85. Sato C., Yasukawa Z., Honda N., Matsuda T., Kitajima K. Identification and adipocyte differentiation-dependent expression of the unique disialic acid residue in an adipose tissue-specific glycoprotein, adipo Q. The Journal of Biological Chemistry 2001, 276:28849-28856.
86. Scheja L., Makowski L., Uysal K.T., Wiesbrock S.M., Shimshek D.R., Meyers D.S., Morgan M., Parker R.A., Hotamisligil G.S. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999, 48:1987-1994.
87. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., Funahashi T., Ouchi N., Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nature Medicine 2005, 11:1096-1103.
88. Shibata R., Skurk C., Ouchi N., Galasso G., Kondo K., Ohashi T., Shimano M., Kihara S., Murohara T., Walsh K. Adiponectin promotes endothelial progenitor cell number and function. FEBS Letters 2008, 582:1607-1612.
89. Shimabukuro M., Higa N., Asahi T., Oshiro Y., Takasu N., Tagawa T., Ueda S., Shimomura I., Funahashi T., Matsuzawa Y. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. The Journal of Clinical Endocrinology and Metabolism 2003, 88:3236-3240.
90. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180.
91. Shore S.A., Terry R.D., Flynt L., Xu A., Hug C. Adiponectin attenuates allergen-induced airway inflammation and hyperresponsiveness in mice. The Journal of Allergy and Clinical Immunology 2006, 118:389-395.
92. Stejskal D., Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: A new marker of metabolic syndrome?. European Journal of Clinical Investigation 2006, 36:621-625.
93. Sulsky R., Magnin D.R., Huang Y., Simpkins L., Taunk P., Patel M., Zhu Y., Stouch T.R., Bassolino-Klimas D., Parker R., et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorganic and Medicinal Chemistry Letters 2007, 17:3511-3515.
94. Summer R., Fiack C.A., Ikeda Y., Sato K., Dwyer D., Ouchi N., Fine A., Farber H.W., Walsh K. Adiponectin deficiency: A model of pulmonary hypertension associated with pulmonary vascular disease. American Journal of Physiology. Lung Cellular and Molecular Physiology 2009, 297:L432-438.
95. Szmitko P.E., Teoh H., Stewart D.J., Verma S. Adiponectin and cardiovascular disease: State of the art?. American Journal of Physiology. Heart and Circulatory Physiology 2007, 292:H1655-H1663.
96. Tan K.C., Xu A., Chow W.S., Lam M.C., Ai V.H., Tam S.C., Lam K.S. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. The Journal of Clinical Endocrinology and Metabolism 2004, 89:765-769.
97. Tao L., Wang Y., Gao E., Zhang H., Yuan Y., Lau W.B., Chan L., Koch W.J., Ma X.L. Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circulation Research 2010, 106:409-417.
98. Thakur V., Pritchard M.T., McMullen M.R., Nagy L.E. Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding. The American Journal of Physiology 2006, 290:G998-G1007.
99. Tilg H., Moschen A.R. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nature Reviews. Immunology 2006, 6:772-783.
100. Torigoe M., Matsui H., Ogawa Y., Murakami H., Murakami R., Cheng X.W., Numaguchi Y., Murohara T., Okumura K. Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men. Clinical Endocrinology 2007, 67:276-281.
101. Trujillo M.E., Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. Journal of Internal Medicine 2005, 257:167-175.
102. Tsao T.S., Tomas E., Murrey H.E., Hug C., Lee D.H., Ruderman N.B., Heuser J.E., Lodish H.F. Role of disulfide bonds in Acrp30/Adiponectin structure and signaling specificity: Different oligomers activate different signal transduction pathways. The Journal of Biological Chemistry 2003, 278:50810-50817.
103. Tso A.W., Xu A., Sham P.C., Wat N.M., Wang Y., Fong C.H., Cheung B.M., Janus E.D., Lam K.S. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: A 10-year prospective study in a Chinese cohort. Diabetes Care 2007, 30:2667-2672.
104. Vanhoutte P.M. Endothelial dysfunction and atherosclerosis. European Heart Journal 1997, 18:E19-E29.
105. Vanhoutte P.M., Tang E., Félétou M., Shimokawa H. Endothelial dysfunction and vascular disease. Acta Physiologica 2009, 196:193-222.
106. Verlohren S., Dubrovska G., Tsang S.Y., Essin K., Luft F.C., Huang Y., Gollasch M. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension 2004, 44:271-276.
107. Waki H., Yamauchi T., Kamon J., Ito Y., Uchida S., Kita S., Hara K., Hada Y., Vasseur F., Froguel P., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. The Journal of Biological Chemistry 2003, 278:40352-40363.
108. Wang Y., Lam K.S., Chan L., Chan K.W., Lam J.B., Lam M.C., Hoo R.C., Mak W.W., Cooper G.J., Xu A. Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. The Journal of Biological Chemistry 2006, 281:16391-16400.
109. Wang Y., Lam J.B., Lam K.S., Liu J., Lam M.C., Hoo R.L., Wu D., Cooper G.J., Xu A. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Research 2006, 66:11462-11470.
110. Wang Y., Lam K.S., Xu A. Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Research 2007, 17:280-282.
111. Wang Y., Lam K.S., Xu J.Y., Lu G., Xu L.Y., Cooper G.J., Xu A. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. The Journal of Biological Chemistry 2005, 280:18341-18347.
112. Wang Y., Lam K.S., Yau M.H., Xu A. Post-translational modifications of adiponectin: Mechanisms and functional implications. The Biochemical Journal 2008, 409:623-633.
113. Wang Y., Lu G., Wong W.P., Vliegenthart J.F., Gerwig G.J., Lam K.S., Cooper G.J., Xu A. Proteomic and functional characterization of endogenous adiponectin purified from fetal bovine serum. Proteomics 2004, 12:3933-3942.
114. Wang Y., Xu A., Knight C., Xu L.Y., Cooper G.J. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. The Journal of Biological Chemistry 2002, 277:19521-19529.
115. Werner C., Kamani C.H., Gensch C., Bohm M., Laufs U. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 2007, 56:2609-2615.
116. Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., Qizilbash N., Collins R., Peto R. Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. Lancet 2009, 373:1083-1096.
117. Xiao Y., Yao L., Li X., Zhong H., Chen X.Y., Tang W.L., Liu S.P., Xu A.M., Zhou Z.G. Relationship of adipocyte fatty acid-binding protein to adiponectin ratio with femoral intima-media thickness and endothelium-dependent vasodilation in patients with newly-diagnosed type 2 diabetes mellitus. Zhonghua Yi Xue Za Zhi 2010, 90:231-235.
118. Xu A., Chan K.W., Hoo R.L., Wang Y., Tan K.C., Zhang J., Chen B., Lam M.C., Tse C., Cooper G.J., et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. The Journal of Biological Chemistry 2005, 280:18073-18080.
119. Xu A., Tso A.W., Cheung B.M., Wang Y., Wat N.M., Fong C.H., Yeung D.C., Janus E.D., Sham P.C., Lam K.S. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: A 5-year prospective study. Circulation 2007, 115:1537-1543.
120. Xu A., Wang H., Hoo R.L., Sweeney G., Vanhoutte P.M., Wang Y., Wu D., Chu W., Qin G., Lam K.S. Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice. Endocrinology 2009, 150:625-633.
121. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. The Journal of Clinical Investigation 2003, 112:91-100.
122. Xu A., Wang Y., Xu J.Y., Stejskal D., Tam S., Zhang J., Wat N.M., Wong W.K., Lam K.S. Adipocyte fatty acid binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clinical Chemistry 2006, 52:405-413.
123. Xu A., Yin S., Wong L., Chan K.W., Lam K.S. Adiponectin ameliorates Dyslipidemia induced by the HIV protease inhibitor ritonavir in Mice. Endocrinology 2004, 145:487-494.
124. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001, 7:941-946.
125. Yeung D.C., Xu A., Cheung C.W., Wat N.M., Yau M.H., Fong C.H., Chau M.T., Lam K.S. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:1796-1802.
126. Yeung D.C., Xu A., Tso A.W., Chow W.S., Wat N.M., Fong C.H., Tam S., Sham P.C., Lam K.S. Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients. Diabetes Care 2009, 32:132-134.
127. Zhou L., Deepa S.S., Etzler J.C., Ryu J., Mao X., Fang Q., Liu D.D., Torres J.M., Jia W., Lechleiter J.D., et al. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase-dependent pathways. The Journal of Biological Chemistry 2009, 284:22426-22435.
128. Zhu W., Cheng K.K., Vanhoutte P.M., Lam K.S., Xu A. Vascular effects of adiponectin: Molecular mechanisms and potential therapeutic intervention. Clinical Science (London) 2008, 114:361-374.